Drug intelligence / Profile preview

HN61001

Development stage: Unknown
Lead developer: Hana Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

HN61001 is a small molecule new molecular entity (NME) under development by Hana Pharm for the induction and maintenance of general anesthesia. As a next-generation anesthetic agent, it is designed to provide rapid onset and recovery with an improved safety profile compared to existing agents like propofol. Hana Pharm, a leader in the South Korean anesthesia market, initiated Phase 1 clinical trials for HN61001 to evaluate its safety, tolerability, and pharmacokinetics. The drug likely exerts its effects through the modulation of GABA-A receptors in the central nervous system, a common mechanism for intravenous general anesthetics.

Other names: HN61001HN-61001HN 61001

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on HN61001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HN61001.

Explore the full profile